Edmund Ingham

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of VRTX stock now.

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Omeros' stock is volatile, driven by the potential FDA approval of narsoplimab for HSCT-TMA, despite past setbacks including an FDA rejection in 2021. Read more here.

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.

ImmunityBio faces competition but offers strong potential with Anktiva. See why IBRX stock remains a buy, backed by a billionaire founder and 2025 prospects.

Read about the struggles facing Humacyte's ATEV technology as FDA approval is delayed, raising financial strain and uncertainty for investors.

Illumina's acquisition of GRAIL was disastrous, but the company is refocusing on its profitable core gene sequencing business. Click for more on ILMN and GRAL.

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks and GLP-1 challenges.

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.